Consilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum9515210.26442/20751753.2018.12.180140Research ArticleInsulin pump Accu-Chek Spirit Combo use in patients with type 1 diabetes mellitus therapyDemidovN. Anicolay13@mail.ruKoteshkovaO. MKoala58@mail.ruPashkovaE. Yuparlodel@mail.ruMishraO. AEndogp5@mail.ruMoscow City Hospital of the Department of Health of MoscowEndocrinological Dispensary of the Department of Health of MoscowS.P.Botkin City Clinical Hospital of the Department of Health of MoscowСity Сlinical Hospital №5 of the Department of Health of the Russian Federation15122018201212813428122021Copyright © 2018, Consilium Medicum2018Introduction. Nowadays type 1 diabetes mellitus (DM) therapy includes insulin replacement therapy with exogenous insulin use like many years ago. Modern technologies of insulin production techniques offer medications with improved characteristics that are designed for basal as well as prandial secretion simulation. Basal-bolus insulin therapy is mostly used in type 1 DM patients. Continuous subcutaneous insulin infusion (CSII) with portative insulin pump (IP) allows to simulate insulin therapy to the rhythm of pancreatic gland physiological secretion. Objective. To evaluate effectiveness of type 1 DM therapy with the use of IP Accu-Chek Spirit Combo in comparison with multiple insulin injections (MII). Study problems. To form a group of type 1 DM patients using IP Accu-Chek Spirit Combo; to form a group of patients using MII comparable by numbers, age and gender composition, and disease duration using IP Accu-Chek Spirit Combo; to perform a statistical analysis of acquired data. Materials and methods. Using data from Moscow Diabetes Mellitus Federal Register (DMFR) a group of 139 patients (group 1) with type 1 DM receiving insulin therapy with IP Accu-Chek Spirit Combo was formed. Control group included 139 patients (group 2) receiving basal-bolus insulin therapy. Statistical analysis was performed using Excel 2016 software. Results. According to Moscow DMFR data 139 patients - 64 (46.0%) male and 75 (54.0%) female with type 1 DM received insulin therapy with IP Accu-Chek Spirit Combo. Mean age of patients was 32.8 (±12.7) years, disease duration - 16.5 (±10.1) years. Mean body mass index was 23.5 (±3.9) kg/m2. Mean glycated hemoglobin level (HbA1c) in patients with type 1 DM receiving IP therapy was 7.4% (±1.1%). A control group with type 1 DM on basal-bolus insulin therapy was formed (n=139). НbA1с level in patients with type 1 DM using IP Accu-Chek Spirit Combo was significantly lower (by 0.6%) than in patients on basal-bolus insulin therapy (p<0.05). Percent of patients with НbАс1<7.0% was significantly higher in patients with type 1 DM using IP (33.8 and 12.9% respectively, p<0.05), and percent of patients with НbА1с≥8.0% was higher in patients on basal-bolus insulin therapy (46.0 and 28.1% respectively, p<0.05). Kinsulin pumpdiabetes mellitusinsulin therapyinsulin dose delivery systemинсулиновая помпасахарный диабетинсулинотерапияинсулиновый дозатор[Pickup J, Keen H. Continuous subcutaneous insulin infusion at 25 years: evidence base for the expanding use of insulin pump therapy in type 1 diabetes. Diabetes Care 2002; 25 (3): 593-98.][Bode B.W, Sabbah H.T, Gross T.M et al. Diabetes management in the new millennium using insulin pump therapy. Diabetes Metab Res Rev 2002; 18 (1): 14-20.][Bode B.W, Steed R.D, Davidson P.C. Reduction in severe hypoglycemia with long-term continuous subcutaneous insulin infusion in type I diabetes. Diabetes Care 2004; 27 (Suppl. 1): s110-s110.][Boland E.A, Grey M, Oesterle A et al. Continuous subcutaneous insulin infusion. A new way to lower risk of severe hypoglycemia, improve metabolic control, and сhance coping in adolescents with type 1 diabetes. Diabetes Care 1999; 22 (11): 1779-84.][Misso M.L, Egberts K.J, Page M et al. Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus. Cochrane Database Syst Rev 2010; 1:CD005103. DOI: 10.1002/14651858.CD005103.pub2][Шестакова М.В., Майоров А.Ю., Филиппов Ю.И. и др. Клинические рекомендации по помповой инсулинотерапии и непрерывному мониторированию гликемии у больных сахарным диабетом. https://www.endocrincentr.ru/sites/default/files/specialists/science/clinic-recomendations/rec_pompo..][Дедов И.И., Шестакова М.В., Майоров А.Ю. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. 2017; 8 https://www.endocrincentr.ru/sites/default/files/specialists/science/clinic-recomendations/algosd.pd..][Heinemann L et al. Insulin pump risks and benefits: a clinical appraisal of pump safety standards, adverse event reporting, and research needs: a joint statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group. Diabetes Care 2015; 38 (4): 716-22.][Bode B.W. An Expert Opinion on Advanced Insulin Pump Use in Youth with Type 1 Diabetes. Diabetes Technol Ther 2017; 19 (3): 145-54.][Karges B. Association of Insulin Pump Therapy vs Insulin Injection Therapy With Severe Hypoglycemia, Ketoacidosis, and Glycemic Control Among Children, Adolescents, and Young Adults With Type 1 Diabetes. JAMA 2017; 318 (14): 1358-66.][Amod A, Carrihill M, Dave J et al. Continuous subcutaneous insulin infusion therapy in type 1 diabetes: 2013 clinical guidelines and recommendations from the Association of Clinical Endocrinologists of South Africa (ACE-SA). JEMDSA 2013; 18 (1): 15-9.][Aronson R et al. Sustained efficacy of insulin pump therapy compared with multiple daily injections in type 2 diabetes: 12-month data from the OpT2mise randomized trial. Diabetes Obes Metab 2016; 18 (5): 500-7.][McCrea D.L. A Primer on Insulin Pump Therapy for Health Care Providers. Nurs Clin North Am 2017; 52 (4): 553-64.][McAuley S.A. Insulin pump basal adjustment for exercise in type 1 diabetes: a randomised crossover study. Diabetologia 2016; 59 (8): 1636-44.][Анциферов М.Б., Котешкова О.М., Клейменова С.А. Инициация терапии с использованием инсулиновой помпы у больных сахарным диабетом 1 типа. Фарматека. 2011; 3: 30-6.][Дедов И.И., Шестакова М.В., Викулова О.К. и др. Сахарный диабет в Российской Федерации: распространенность, заболеваемость, смертность, параметры углеводного обмена и структура сахароснижающей терапии по данным Федерального регистра сахарного диабета, статус 2017 г. Сахарный диабет. 2018; 21 (3): 144-59. DOI: 10.14341/DM9686][Демидов Н.А., Мишра О.А., Анциферов М.Б. Сахарный диабет 1 типа в Москве - 2018 г. (по данным Московского сегмента Федерального регистра сахарного диабета). Фарматека. 2018; 11; 7-78. DOI: https: //dx.doi.org/10.18565/pharmateca.2018.11.74-78]